Home » Industry Calls U.S. Supreme Court Ruling on Isolated DNA Patentability ‘Troubling’
Industry Calls U.S. Supreme Court Ruling on Isolated DNA Patentability ‘Troubling’
July 10, 2013
The U.S. Supreme Court June 13 dismissed Myriad Genetics’ patent-eligibility claims on the BRCA1 and BRCA2 genes commonly associated with breast and ovarian cancer, while upholding the company’s patents on the diagnostic technology it created from those genes.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor